ArticleScientific reports2025
Robust screening of atrial fibrillation with distribution classification.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Wearable Flexible Sensors for Cardiovascular Disease Monitoring.Advanced materials (Deerfield Beach, Fla.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atrial fibrillation (AF) correlates with an increased risk of all-cause mortality or stroke, mainly due to undiagnosed patients and undertreatment. Its screening is thus a key challenge, for which machine learning methods hold the promise of cheaper and faster campaigns. The robustness of such methods to varying artifacts, noise, and conditions is then crucial. We introduce the first distributional support vector machine (SVM) for robust detection of AF from short, noisy electrocardiograms. It achieves state-of-the-art performance and unprecedented robustness on the screening problem while only leveraging one interpretable feature and little training data. We illustrate these advantages by evaluating on other data sources (cross-data-set) and through sensitivity studies. These strengths result from two main components: (i) preliminary peak detection enabling robust computation of medically relevant features; and (ii) a mathematically principled way of aggregating those features to compare their full distributions. This establishes our algorithm as a relevant candidate for screening campaigns.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.